Allogeneic HSCT

Back to Top
Unlike the other chemotherapy regimen pages, this one is not disease-specific. Rather, this is a gathering point for all allogeneic hematopoietic stem cell transplant (HSCT) conditioning regimens. Unless otherwise specified, the day before HSCT is day -1, the day of HSCT is day 0, and the day after HSCT is day +1. As with the rest of the HemOnc.org website, the focus here is on regimens used in the treatment of hematologic or oncologic conditions; there are roles for allogeneic HSCT outside of hematology/oncology but these use cases are considered to be out of scope.
These links will take you to highly related pages:
*Cellular therapy conditioning regimens
*Graft versus host disease (GVHD)
*Hepatic veno-occlusive disease (VOD)
*We have moved How I Treat articles to a dedicated page.
Last updated on 2024-12-02:25 regimens on this page
46 variants on this page
=Myeloablative regimens, all lines of therapy=
==BuCyTBI==
BuCyTBI: Busulfan, Cyclophosphamide, Total Body Irradiation
===Regimen===
Study 	Evidence
Fefer et al. 1979	Pilot, fewer than 20 pts
====Chemotherapy====
*Busulfan (Myleran) 5 mg/kg IV once on day -6
*Cyclophosphamide (Cytoxan) 60 mg/kg IV once per day on days -5 & -4
====Radiotherapy====
*TBI 920 rads on day 0
====Immunotherapy====
*Allogeneic stem cells transfused on day 0
One course
===References===
#Fefer A, Cheever MA, Thomas ED, Boyd C, Ramberg R, Glucksberg H, Buckner CD, Storb R. Disappearance of Ph1-positive cells in four patients with chronic granulocytic leukemia after chemotherapy, irradiation and marrow transplantation from an identical twin. N Engl J Med. 1979 Feb 15;300(7):333-7. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
==Busulfan & Cyclophosphamide==
BuCy: Busulfan & Cyclophosphamide
===Regimen variant #1, 3.2 x 4/120===
Study 	Dates of enrollment 	Evidence 	Comparator 	Comparative Efficacy 	Non-relapse mortality
Kröger et al. 2017 (RICMAC) 	2004-2012 	Phase 3 (C) 	Bu/Flu RIC allo HSCT 	Might have shorter OS 	
Lee et al. 2013 (COSAH C-005) 	2005-2009 	Phase 3 (C) 	Busulfan & Fludarabine 	Seems to have longer OS (secondary endpoint) 	
Rambaldi et al. 2015 (GITMO-AMLR2)	2008-2012 	Phase 3 (C) 	Busulfan & Fludarabine 	 	Seems to have lower 1-year non-relapse mortality
Scott et al. 2017 (BMT CTN 0901) 	2011-2014 	Phase 3 (C) 	1a. BuFlu1b. FluMel 	Seems to have longer OS (primary endpoint)OS18: 76.4% vs 63.4%(HR 0.64, 95% CI 0.38-0.98)	
Zhang et al. 2023 	2016-01 to 2020-02 	Phase 3 (E-switch-ooc)	TBI-Cy 	Non-inferior OS24 (primary endpoint)OS24: 76.6% vs 79.4% 	Similar NRM
Xuan et al. 2023 	2016-04-18 to 2019-09-30	Phase 3 (C) 	Busulfan, Cyclophosphamide, Decitabine, G-CSF	Lower CIR24 	
====Chemotherapy====
*Busulfan (Myleran) 3.2 mg/kg IV once per day on days -7 to -4 (total dose: 12.8 mg/kg)
*Cyclophosphamide (Cytoxan) 60 mg/kg IV once per day on days -3 and -2 (total dose: 120 mg/kg)
====Immunotherapy====
*Allogeneic stem cells transfused on day 0
====GVHD prophylaxis====
Per GITMO-AMLR2:
*Cyclosporine 1.5 mg/kg IV twice per day, started on day -1, adjusted to a trough concentration of 200 ng/mL or more
*Methotrexate (MTX) 15 mg/m2 IV once on day +1, then 10 mg/m2 IV once per day on days +3, +6, +11
====Supportive therapy====
*Filgrastim (Neupogen) 450 mcg SC once per day, starting on day +5 and continued until ANC greater than 3000/μL
One course
===Regimen variant #2, 0.8 x 16/120===
Study 	Dates of enrollment 	Evidence 	Comparator	Comparative Efficacy	Non-relapse mortality
Andersson et al. 2002	1996-06 to 1997-12 	Phase 2 	 	 	
Ling et al. 2023 	2015-11-20 to 2019-09-30	Phase 3 (C)	BuFlu 	 	Seems to have lower TRM12
====Chemotherapy====
*Busulfan (Myleran) 0.8 mg/kg IV four times per per day on days -7 to -4 (total dose: 12.8 mg/kg)
*Cyclophosphamide (Cytoxan) 60 mg/kg IV once per day on days -3 and -2 (total dose: 120 mg/kg)
====Immunotherapy====
*Allogeneic stem cells transfused on day 0
One course
===Regimen variant #3, 1 x 16/200===
Study 	Evidence
Santos et al. 1983	Non-randomized
Note: the day of allogeneic stem cell transplant is not specified in the protocol.
====Chemotherapy====
*Busulfan (Myleran) 1 mg/kg IV every 6 hours on days 1 to 4 (total dose: 16 mg/kg)
*Cyclophosphamide (Cytoxan) 50 mg/kg IV once per day on days 5 to 8 (total dose: 200 mg/kg)
====Immunotherapy====
*Allogeneic stem cells transfused on unspecified day
One course
===References===
#Santos GW, Tutschka PJ, Brookmeyer R, Saral R, Beschorner WE, Bias WB, Braine HG, Burns WH, Elfenbein GJ, Kaizer H, Mellits D, Sensenbrenner LL, Stuart RK, Yeager AM. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med. 1983 Dec 1;309(22):1347-53. link to original article dosing details in abstract have been reviewed by our editors EuroPMC
#Andersson BS, Kashyap A, Gian V, Wingard JR, Fernandez H, Cagnoni PJ, Jones RB, Tarantolo S, Hu WW, Blume KG, Forman SJ, Champlin RE. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant. 2002;8(3):145-54. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
#COSAH C-005: Lee JH, Joo YD, Kim H, Ryoo HM, Kim MK, Lee GW, Lee JH, Lee WS, Park JH, Bae SH, Hyun MS, Kim DY, Kim SD, Min YJ, Lee KH. Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine. J Clin Oncol. 2013 Feb 20;31(6):701-9. Epub 2012 Nov 5. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00774280
#GITMO-AMLR2: Rambaldi A, Grassi A, Masciulli A, Boschini C, Micò MC, Busca A, Bruno B, Cavattoni I, Santarone S, Raimondi R, Montanari M, Milone G, Chiusolo P, Pastore D, Guidi S, Patriarca F, Risitano AM, Saporiti G, Pini M, Terruzzi E, Arcese W, Marotta G, Carella AM, Nagler A, Russo D, Corradini P, Alessandrino EP, Torelli GF, Scimè R, Mordini N, Oldani E, Marfisi RM, Bacigalupo A, Bosi A. Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2015 Nov;16(15):1525-36. Epub 2015 Sep 28. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT01191957
#BMT CTN 0901: Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, Maziarz RT, Warlick ED, Fernandez HF, Alyea EP, Hamadani M, Bashey A, Giralt S, Geller NL, Leifer E, Le-Rademacher J, Mendizabal AM, Horowitz MM, Deeg HJ, Horwitz ME. Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. J Clin Oncol. 2017 Apr 10;35(11):1154-1161. Epub 2017 Feb 13. link to original article link to PMC article EuroPMC NCT01339910
# RICMAC: Kröger N, Iacobelli S, Franke GN, Platzbecker U, Uddin R, Hübel K, Scheid C, Weber T, Robin M, Stelljes M, Afanasyev B, Heim D, Deliliers GL, Onida F, Dreger P, Pini M, Guidi S, Volin L, Günther A, Bethge W, Poiré X, Kobbe G, van Os M, Brand R, de Witte T. Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial). J Clin Oncol. 2017 Jul 1;35(19):2157-2164. Epub 2017 May 2. link to original article EuroPMC NCT01203228
#Zhang H, Fan Z, Huang F, Han L, Xu Y, Xu N, Deng L, Wang S, Lin D, Luo X, Zhang Q, Liu X, Li X, Liang X, Xie S, Qu H, Yu S, Zhou H, Shi P, Xuan L, Lin R, Liu H, Jin H, Sun J, Liu Q. Busulfan Plus Cyclophosphamide Versus Total Body Irradiation Plus Cyclophosphamide for Adults Acute B Lymphoblastic Leukemia: An Open-Label, Multicenter, Phase III Trial. J Clin Oncol. 2023 Jan 10;41(2):343-353. Epub 2022 Sep 9. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors EuroPMC NCT02670252
#Xuan L, Dai M, Jiang E, Wang Y, Huang F, Fan Z, Xu N, Nie D, Liang X, Chen H, Ye J, Shi P, Liu H, Jin H, Lin R, Yan C, Zhang Y, Sun J, Han M, Liu Q. The effect of granulocyte-colony stimulating factor, decitabine, and busulfan-cyclophosphamide versus busulfan-cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from myelodysplastic syndrome undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol. 2023 Mar;10(3):e178-e190. Epub 2023 Jan 23. link to original article dosing details in abstract have been reviewed by our editors EuroPMC NCT02744742
#Ling Y, Xuan L, Xu N, Huang F, Fan Z, Guo Z, Xu X, Liu H, Lin R, Yu S, Zhang H, Jin H, Wu M, Liu C, Liang X, Ou R, Zhang Y, Liu X, Qu H, Zhai X, Sun J, Zhao Y, Liu Q. Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III Trial. J Clin Oncol. 2023 Oct 10;41(29):4632-4642. Epub 2023 Jun 19. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT02487069
==Busulfan, Cyclophosphamide, Decitabine, G-CSF==
===Regimen===
Study 	Dates of enrollment 	Evidence 	Comparator	Comparative Efficacy
Xuan et al. 2023	2016-04-18 to 2019-09-30	Phase 3 (E-esc)	BuCy 	Higher CIR24 (primary endpoint)CIR24: 10.9% vs 24.8%(HR 0.39, 95% CI 0.19-0.79)
====Chemotherapy====
*Busulfan (Myleran) 3.2 mg/kg IV once per day on days -7 to -4 (total dose: 12.8 mg/kg)
*Cyclophosphamide (Cytoxan) 60 mg/kg IV once per day on days -3 & -2 (total dose: 120 mg/kg)
*Decitabine (Dacogen) 20 mg/m2 IV once per day on days -14 to -10
====Growth factor therapy====
*G-CSF 5 mcg/kg SC once per day on days -17 to -10
====Immunotherapy====
*Allogeneic stem cells transfused on day 0
One course
===References===
#Xuan L, Dai M, Jiang E, Wang Y, Huang F, Fan Z, Xu N, Nie D, Liang X, Chen H, Ye J, Shi P, Liu H, Jin H, Lin R, Yan C, Zhang Y, Sun J, Han M, Liu Q. The effect of granulocyte-colony stimulating factor, decitabine, and busulfan-cyclophosphamide versus busulfan-cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from myelodysplastic syndrome undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol. 2023 Mar;10(3):e178-e190. Epub 2023 Jan 23. link to original article dosing details in abstract have been reviewed by our editors EuroPMC NCT02744742
==Busulfan & Fludarabine==
BuFlu: Busulfan & Fludarabine
Flu/Bu: Fludarabine & Busulfan
===Regimen variant #1===
Study 	Dates of enrollment 	Evidence 	Comparator 	Comparative Efficacy	Comparative Toxicity
Ling et al. 2023	2015-11-20 to 2019-09-30	Phase 3 (E-de-esc)	Busulfan & Cyclophosphamide	 	Seems to have lower TRMM12 (primary endpoint)
Diseases Studied: Acute myeloid leukemia
====Chemotherapy====
*Busulfan (Myleran) 0.8 mg/kg IV four times per day for 2 hour infusions on days -6 to -3
*Fludarabine (Fludara) 30 mg/m2 IV once per day on days -7 to -3
====Immunotherapy====
*Allogeneic stem cells transfused on day 0
One course
===Regimen variant #2===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy	Comparative Toxicity
Rambaldi et al. 2015 (GITMO-AMLR2)	2008-2012 	Phase 3 (E-switch-ic)	Busulfan & Cyclophosphamide	 	Seems to have lower NRM12 (primary endpoint)
Diseases Studied: Acute myeloid leukemia
Graft types studied: Bone Marrow, Mobilized Peripheral Blood Stem Cells
====Chemotherapy====
*Busulfan (Myleran) 0.8 mg/kg IV four times per day for 2 hour infusions on days -6 to -3
*Fludarabine (Fludara) 30 mg/m2 IV once per day on days -6 to -3
====GVHD prophylaxis, pre-transplant====
*Antithymocyte globulin, rabbit ATG (Thymoglobulin) by the following donor-based criteria:
**Matched unrelated donors: 0.5 mg/kg IV once on day -3, then 2 mg/kg IV once on day -2, then 2.5 mg/kg IV once on day -1
**Mismatched donors: total ATG dose could be increased to 7.5 mg/kg
====Immunotherapy====
*Allogeneic stem cells transfused on day 0
====GVHD prophylaxis, post-transplant====
*Cyclosporine 1.5 mg/kg IV twice per day, started on day -1, adjusted to a trough concentration of 200 ng/mL or more
*Methotrexate (MTX) 15 mg/m2 IV once on day +1, then 10 mg/m2 IV once per day on days +3, +6, +11
One course
===Regimen variant #3===
Study 	Dates of enrollment	Evidence 	Comparator	Comparative Efficacy
Andersson et al. 2008 	1997-2005 	Non-randomized	 	Suggested improved outcomes, but shorter follow up
Kanakry et al. 2014 (J0844) 	2009-2011 	Phase 2 	 	
Mielcarek et al. 2016 (FHCC 2541.00)	2011-2013 	Phase 2 	 	-
Diseases Studied: Acute myeloid leukemia, Myelodysplastic syndrome, Acute lymphocytic leukemia, Chronic myeloid leukemia, Non-Hodgkin lymphoma
Graft types studied: Matched Related / Unrelated Donor Bone Marrow, Mobilized Peripheral Blood Stem Cells
====Chemotherapy====
*Busulfan (Myleran) 130 mg/m2 IV over 3 hours once per day on days -6 to -3
**Dosing targeted for optimal pharmacokinetics but different parameters each institution, please consult the original publication for optimal levels
*Fludarabine (Fludara) 40 mg/m2 IV over 60 minutes once per day on days -6 to -3, given first
====GVHD prophylaxis, pre-transplant====
*Antithymocyte globulin, rabbit ATG (Thymoglobulin) by the following donor-based criteria:
**Unrelated or mismatched donors: 0.5 mg/kg IV once on day -3, then 1.5 mg/kg IV once on day -2, then 2 mg/kg IV once on day -1
====Immunotherapy====
*Allogeneic stem cells transfused on day 0
====GVHD prophylaxis, post-transplant====
#1 Tacrolimus & methotrexate based (Andersson et al.)
*Tacrolimus (Prograf) (dose/route not specified)
*Methotrexate (MTX) 5 mg/m2 (route not specified) once per day on days +1, +3, +6, +11
====Supportive therapy====
*All patients received Filgrastim (Neupogen) SC once per day from day +7 until achieving an absolute neutrophil count (ANC) ≥1.5 x 109/L for three days
*Phenytoin (Dilantin) prophylaxis used during and for one day after IV busulfan
#2 Post-Transplant Cy based (Kanakry et al. and FHCC 2541.00)
====GVHD prophylaxis====
*Cyclophosphamide (Cytoxan) 50 mg/kg IV once per day on days +3 & +4 (used alone in Kanakry et al. when all patients received bone marrow grafts)
*± Cyclosporine intravenous loading dose of CSP was given on day 5, followed by subsequent twice per day dosing adjusted to maintain whole blood trough at 120 to 360 ng/mL. In abscence of GVHD Cyclosporine was tapered from day +56 through day +126 (used in FHCC 2541.00 with PBSCT grafts)
====Supportive therapy====
*Mesna (Mesnex) given with cyclophosphamide
One course
===Regimen variant #4===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Lee et al. 2013 (COSAH C-005)	2005-2009 	Phase 3 (E-switch-ic)	Busulfan & Cyclophosphamide	Seems to have shorter OS (secondary endpoint)
Diseases Studied: Acute myeloid leukemia, Myelodysplastic syndrome, Acute lymphocytic leukemia, Chronic myeloid leukemia, Myelofibrosis
Graft types studied: Matched Related / Unrelated Donor Bone Marrow, Mobilized Peripheral Blood Stem Cells
====Chemotherapy====
*Busulfan (Myleran) 3.2 mg/kg IV once per day on days -7 to -4, given first on days overlapping with fludarabine (total dose: 12.8 mg/kg)
*Fludarabine (Fludara) 30 mg/m2 IV once per day on days -6 to -2, given second on days overlapping with busulfan
====Immunotherapy====
*Allogeneic stem cells transfused on day 0
====GVHD prophylaxis====
*"Cyclosporine (dose/route not specified)
*Methotrexate (MTX) (dose/route not specified) "according to the discretion of the attending physician"
====Supportive therapy====
*Filgrastim (Neupogen) 450 mcg SC once per day, starting on day +5 and continued until ANC greater than 3000/μL
One course
===Regimen variant #5===
Study 	Dates of enrollment	Evidence
Russell et al. 2002	1999-2001 	Phase 2
Diseases Studied: Acute myeloid leukemia, Myelodysplastic syndrome, Chronic myeloid leukemia, Chronic lymphocytic leukemia, Non-Hodgkin lymphoma, Hypereosinophilic syndrome
Graft types studied: Matched Related / Unrelated Donor Bone Marrow or Mobilized Peripheral Blood Stem Cells
====Chemotherapy====
*Busulfan (Myleran) 3.2 mg/kg (ideal body weight) IV over 3 hours once per day on days -5 to -2
*Fludarabine (Fludara) 50 mg/m2 IV once per day on days -6 to -2
====Immunotherapy====
*Allogeneic stem cells transfused on day 0
====GVHD prophylaxis====
*Antithymocyte globulin, rabbit ATG (Thymoglobulin) 0.5 mg/kg IV once on day -2, then 2 mg/kg IV once per day on days -1 & 0 (total dose of 4.5 mg/kg)
*Cyclosporine IV or PO twice per day, with doses adjusted to maintain cyclosporine levels of 150 to 400 umol/L
*Methotrexate (MTX) 15 mg/m2 (route not specified) once on day 1, then 10 mg/m2 (route not specified) once per day on days +3, +6, +11
====Supportive therapy====
*Leucovorin (Folinic acid) 5 mg started 24 hours after each dose of methotrexate and continued every 6 hours until 12 hours before the next dose of methotrexate
*Phenytoin (Dilantin) "loading" PO/IV, dosed to maintain therapeutic levels of 40 to 80 umol/L on days -5 to -2
One course
===References===
#Russell JA, Tran HT, Quinlan D, Chaudhry A, Duggan P, Brown C, Stewart D, Ruether JD, Morris D, Glick S, Gyonyor E, Andersson BS. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant. 2002;8(9):468-76. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
#de Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R, Shpall EJ, Shahjahan M, Pierre B, Giralt S, Korbling M, Russell JA, Champlin RE, Andersson BS. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood. 2004 Aug 1;104(3):857-64. Epub 2004 Apr 8. link to original article EuroPMC
#Andersson BS, de Lima M, Thall PF, Wang X, Couriel D, Korbling M, Roberson S, Giralt S, Pierre B, Russell JA, Shpall EJ, Jones RB, Champlin RE. Once daily IV busulfan and fludarabine (IV Bu-Flu) compares favorably with IV busulfan and cyclophosphamide (IV BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant. 2008;14(6):672-84. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors EuroPMC
#COSAH C-005: Lee JH, Joo YD, Kim H, Ryoo HM, Kim MK, Lee GW, Lee JH, Lee WS, Park JH, Bae SH, Hyun MS, Kim DY, Kim SD, Min YJ, Lee KH. Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine. J Clin Oncol. 2013 Feb 20;31(6):701-9. Epub 2012 Nov 5. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00774280
#J0844: Kanakry CG, O'Donnell PV, Furlong T, de Lima MJ, Wei W, Medeot M, Mielcarek M, Champlin RE, Jones RJ, Thall PF, Andersson BS, Luznik L. Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. J Clin Oncol. 2014; 32(31):3497-505. Epub 2014 Sep 29. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00809276
#FHCC 2541.00: Mielcarek M, Furlong T, O'Donnell PV, Storer BE, McCune JS, Storb R, Carpenter PA, Flowers ME, Appelbaum FR, Martin PJ. Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. Blood. 2016;127(11):1502-8. Epub 2016 Jan 13. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article EuroPMC NCT01427881
#GITMO-AMLR2: Rambaldi A, Grassi A, Masciulli A, Boschini C, Micò MC, Busca A, Bruno B, Cavattoni I, Santarone S, Raimondi R, Montanari M, Milone G, Chiusolo P, Pastore D, Guidi S, Patriarca F, Risitano AM, Saporiti G, Pini M, Terruzzi E, Arcese W, Marotta G, Carella AM, Nagler A, Russo D, Corradini P, Alessandrino EP, Torelli GF, Scimè R, Mordini N, Oldani E, Marfisi RM, Bacigalupo A, Bosi A. Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2015 Nov;16(15):1525-36. Epub 2015 Sep 28. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT01191957
#MDACC 2011-0628: Andersson BS, Thall PF, Ma J, Valdez BC, Bassett R Jr, Chen J, Ahmed S, Alousi A, Bashir Q, Ciurea S, Gulbis A, Cool R, Kawedia J, Hosing C, Kebriaei P, Kornblau S, Myers A, Oran B, Rezvani K, Shah N, Shpall E, Parmar S, Popat UR, Nieto Y, Champlin RE. A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantation. Bone Marrow Transplant. 2022 Aug;57(8):1295-1303. Epub 2022 May 24. link to original article link to PMC article EuroPMC NCT01471444
#Ling Y, Xuan L, Xu N, Huang F, Fan Z, Guo Z, Xu X, Liu H, Lin R, Yu S, Zhang H, Jin H, Wu M, Liu C, Liang X, Ou R, Zhang Y, Liu X, Qu H, Zhai X, Sun J, Zhao Y, Liu Q. Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III Trial. J Clin Oncol. 2023 Oct 10;41(29):4632-4642. Epub 2023 Jun 19. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT02487069
==Cyclophosphamide & TBI==
Cy/TBI: Cyclophosphamide & Total Body Irradiation
TBI-CY: Total Body Irradiation & Cyclophosphamide
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy 	Non-relapse mortality
Rudolph et al. 1973 	1968-1970 	Non-randomized 	 	 	
Fefer et al. 1982 	1971-1980 	Non-randomized, fewer than 20 pts	 	 	
Thomas et al. 1979 	1976-1977 	Non-randomized 	 	 	
Blume et al. 1980 	1976-1979 	Non-randomized, fewer than 20 pts	 	 	
Johnson et al. 1981 	1976-1980 	Non-randomized 	 	 	
Brochstein et al. 1987 	1979-1985 	Non-randomized 	 	 	
Goldman et al. 1986 	1981-1984 	Non-randomized 	 	 	
Kersey et al. 1987 	1982-1985 	Quasi-randomized 	Auto HSCT 	Longer RFS 	
Hansen et al. 1998 	1985-1994 	Non-randomized 	 	 	
Sebban et al. 1994 (LALA 87) 	1986-1991 	Phase 3 (E-esc) 	Chemotherapy or Auto HSCT	Did not meet co-primary endpoints of DFS/OS	
Zittoun et al. 1995 	1986-1993 	Phase 3 (E-esc) 	Intensive chemotherapy 	Longer DFS 	
Thomas et al. 2004 (LALA-94) 	1994-2002 	Non-randomized part of RCT 	 	 	
Bornhäuser et al. 2012 (9005-2003)	2004-2009 	Phase 3 (C) 	Fludarabine & TBI 	Did not meet secondary efficacy endpoints 	Did not meet primary endpoint of NRM
Zhang et al. 2023 	2016-01 to 2020-02 	Phase 3 (C) 	BuCy 	Non-inferior OS24 	Similar NRM
Details in most of the manuscripts are limited.
====Chemotherapy====
*Cyclophosphamide (Cytoxan) 60 mg/kg IV once per day on days -3 & -2
====Radiotherapy====
*Total body irradiation by the following study-specific criteria:
**Zhang et al. 2023: 450 cGy once per day on days -5 & -4 (900 cGy total)
**Other studies: 1000 to 1200 cGy total
====Immunotherapy====
*Allogeneic stem cells transfused on day 0
One course
===References===
#Rudolph RH, Fefer A, Thomas ED, Buckner CD, Clift RA, Storb R. Isogeneic marrow grafts for hematologic malignancy in man. Arch Intern Med. 1973 Aug;132(2):279-85. link to original article EuroPMC
##Update: Fefer A, Einstein AB, Thomas ED, Buckner CD, Clift RA, Glucksberg H, Neiman PE, Storb R. Bone-marrow transplantation for hematologic neoplasia in 16 patients with identical twins. N Engl J Med. 1974 Jun 20;290(25):1389-93. link to original article EuroPMC
#Thomas ED, Sanders JE, Flournoy N, Johnson FL, Buckner CD, Clift RA, Fefer A, Goodell BW, Storb R, Weiden PL. Marrow transplantation for patients with acute lymphoblastic leukemia in remission. Blood. 1979 Aug;54(2):468-76. link to original article dosing details in abstract have been reviewed by our editors EuroPMC
#Blume KG, Beutler E, Bross KJ, Chillar RK, Ellington OB, Fahey JL, Farbstein MJ, Forman SJ, Schmidt GM, Scott EP, Spruce WE, Turner MA, Wolf JL. Bone-marrow ablation and allogeneic marrow transplantation in acute leukemia. N Engl J Med. 1980 May 8;302(19):1041-6. link to original article EuroPMC
#Johnson FL, Thomas ED, Clark BS, Chard RL, Hartmann JR, Storb R. A comparison of marrow transplantation with chemotherapy for children with acute lymphoblastic leukemia in second or subsequent remission. N Engl J Med. 1981 Oct 8;305(15):846-51. link to original article EuroPMC
#Fefer A, Cheever MA, Greenberg PD, Appelbaum FR, Boyd CN, Buckner CD, Kaplan HG, Ramberg R, Sanders JE, Storb R, Thomas ED. Treatment of chronic granulocytic leukemia with chemoradiotherapy and transplantation of marrow from identical twins. N Engl J Med. 1982 Jan 14;306(2):63-8. link to original article EuroPMC
#Goldman JM, Apperley JF, Jones L, Marcus R, Goolden AW, Batchelor R, Hale G, Waldmann H, Reid CD, Hows J, Gordon-Smith E, Catovsky D, Galton DAG. Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med. 1986 Jan 23;314(4):202-7. EuroPMC
#Kersey JH, Weisdorf D, Nesbit ME, LeBien TW, Woods WG, McGlave PB, Kim T, Vallera DA, Goldman AI, Bostrom B, Hurd D, Ramsay NKC. Comparison of autologous and allogeneic bone marrow transplantation for treatment of high-risk refractory acute lymphoblastic leukemia. N Engl J Med. 1987 Aug 20;317(8):461-7. link to original article EuroPMC
#Brochstein JA, Kernan NA, Groshen S, Cirrincione C, Shank B, Emanuel D, Laver J, O'Reilly RJ. Allogeneic bone marrow transplantation after hyperfractionated total-body irradiation and cyclophosphamide in children with acute leukemia. N Engl J Med. 1987 Dec 24;317(26):1618-24. link to original article EuroPMC
#LALA 87: Sebban C, Lepage E, Vernant JP, Gluckman E, Attal M, Reiffers J, Sutton L, Racadot E, Michallet M, Maraninchi D, Dreyfus F, Fiere D; French Group of Therapy of Adult Acute Lymphoblastic Leukemia. Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: a comparative study. J Clin Oncol. 1994 Dec;12(12):2580-7. link to original article EuroPMC
##Update: Thiebaut A, Vernant JP, Degos L, Huguet FR, Reiffers J, Sebban C, Lepage E, Thomas X, Fière D. Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation: a follow-up report of the French protocol LALA 87. Hematol Oncol Clin North Am. 2000 Dec;14(6):1353-66. link to original article EuroPMC
#Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L, Leoni F, Damasio E, Visani G, Papa G, Caronia F, Hayat M, Stryckmans P, Rotoli B, Leoni P, Peetermans ME, Dardenne M, Vegna ML, Petti MC, Solbu G, Suciu S; EORTC; Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med. 1995 Jan 26;332(4):217-23. link to original article dosing details in abstract have been reviewed by our editors EuroPMC
#Hansen JA, Gooley TA, Martin PJ, Appelbaum F, Chauncey TR, Clift RA, Petersdorf EW, Radich J, Sanders JE, Storb RF, Sullivan KM, Anasetti C. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med. 1998 Apr 2;338(14):962-8. link to original article EuroPMC
#LALA-94: Thomas X, Boiron JM, Huguet F, Dombret H, Bradstock K, Vey N, Kovacsovics T, Delannoy A, Fegueux N, Fenaux P, Stamatoullas A, Vernant JP, Tournilhac O, Buzyn A, Reman O, Charrin C, Boucheix C, Gabert J, Lhéritier V, Fiere D. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol. 2004 Oct 15;22(20):4075-86. Epub 2004 Sep 7. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00002700
##Update: Vey N, Thomas X, Picard C, Kovascovicz T, Charin C, Cayuela JM, Dombret H, Dastugue N, Huguet F, Bastard C, Stamatoulas A, Giollant M, Tournilhac O, Macintyre E, Buzyn A, Bories D, Kuentz M, Dreyfus F, Delannoy A, Raynaud S, Gratecos N, Bordessoule D, de Botton S, Preudhomme C, Reman O, Troussard X, Pigneux A, Bilhou C, Vernant JP, Boucheix C, Gabert J; Swiss Group for Clinical Cancer Research. Allogeneic stem cell transplantation improves the outcome of adults with t(1;19)/E2A-PBX1 and t(4;11)/MLL-AF4 positive B-cell acute lymphoblastic leukemia: results of the prospective multicenter LALA-94 study. Leukemia. 2006 Dec;20(12):2155-61. Epub 2006 Oct 12. link to original article EuroPMC
#9005-2003: Bornhäuser M, Kienast J, Trenschel R, Burchert A, Hegenbart U, Stadler M, Baurmann H, Schäfer-Eckart K, Holler E, Kröger N, Schmid C, Einsele H, Kiehl MG, Hiddemann W, Schwerdtfeger R, Buchholz S, Dreger P, Neubauer A, Berdel WE, Ehninger G, Beelen DW, Schetelig J, Stelljes M. Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. Lancet Oncol. 2012 Oct;13(10):1035-44. Epub 2012 Sep 7. link to original article dosing details in abstract have been reviewed by our editors EuroPMC NCT00150878
#Retrospective: Copelan EA, Hamilton BK, Avalos B, Ahn KW, Bolwell BJ, Zhu X, Aljurf M, van Besien K, Bredeson C, Cahn JY, Costa LJ, de Lima M, Gale RP, Hale GA, Halter J, Hamadani M, Inamoto Y, Kamble RT, Litzow MR, Loren AW, Marks DI, Olavarria E, Roy V, Sabloff M, Savani BN, Seftel M, Schouten HC, Ustun C, Waller EK, Weisdorf DJ, Wirk B, Horowitz MM, Arora M, Szer J, Cortes J, Kalaycio ME, Maziarz RT, Saber W. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood. 2013 Dec 5;122(24):3863-70. Epub 2013 Sep 24. link to original article link to PMC article EuroPMC
#Zhang H, Fan Z, Huang F, Han L, Xu Y, Xu N, Deng L, Wang S, Lin D, Luo X, Zhang Q, Liu X, Li X, Liang X, Xie S, Qu H, Yu S, Zhou H, Shi P, Xuan L, Lin R, Liu H, Jin H, Sun J, Liu Q. Busulfan Plus Cyclophosphamide Versus Total Body Irradiation Plus Cyclophosphamide for Adults Acute B Lymphoblastic Leukemia: An Open-Label, Multicenter, Phase III Trial. J Clin Oncol. 2023 Jan 10;41(2):343-353. Epub 2022 Sep 9. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors EuroPMC NCT02670252
#SWOG S9920: NCT00005866
==Etoposide & TBI==
===Regimen variant #1, weight-based etoposide===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Balduzzi et al. 2005 	1995-2000 	Quasi-randomized	Chemotherapy	Seems to have longer DFS
Peters et al. 2015 (ALL-SCT-BFM 2003)	2003-2011 	Non-randomized 	 	
This regimen was evaluated in the treatment of high-risk pediatric acute lymphoblastic leukemia in CR1.
====Chemotherapy====
*Etoposide (Vepesid) 60 mg/kg (maximum dose of 3600 mg) IV once on day -3
====Radiotherapy====
*Total body irradiation (TBI) 200 cGy twice per day in 6 fractions on days -6 to -4 with lung shielding at 1000 cGy (total dose: 1200 cGy)
====Immunotherapy====
*Allogeneic stem cells transfused on day 0
One course
===Regimen variant #2, BSA-based etoposide===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Peters et al. 2020 (FORUM)	2013-2018 	Phase 3 (C)	1a. Busulfan, Fludarabine, Thiotepa1b. Fludarabine, Thiotepa, Treosulfan	Longer OS (primary endpoint)
This regimen was evaluated in the treatment of high-risk pediatric acute lymphoblastic leukemia in CMR.
====Chemotherapy====
*Etoposide (Vepesid) 1800 mg/m2 (maximum dose of 3600 mg) IV once on day -3
====Radiotherapy====
*Total body irradiation (TBI) 200 cGy twice per day in 6 fractions on days -6 to -4 with lung shielding at 1000 cGy (total dose: 1200 cGy)
====Immunotherapy====
*Allogeneic stem cells transfused on day 0
One course
===Regimen variant #3, 1320 cGy===
Study 	Dates of enrollment	Evidence
Rowe et al. 2005 (MRC UKALL XII/ECOG E2993)	1993-2003 	Non-randomized part of phase 3 RCT
Note: this is the same preparative regimen used for autologous transplant for certain patients; see reference for details. This regimen was evaluated in the treatment of acute lymphoblastic leukemia in CR1.
====Chemotherapy====
*Etoposide (Vepesid) 60 mg/kg IV once on day -3
====Radiotherapy====
*Total body irradiation (TBI) 220 cGy twice per day in 6 fractions on days -6 to -4 (total dose: 1320 cGy)
====Immunotherapy====
*Allogeneic stem cells transfused on day 0
One course
===References===
#Balduzzi A, Valsecchi MG, Uderzo C, De Lorenzo P, Klingebiel T, Peters C, Stary J, Felice MS, Magyarosy E, Conter V, Reiter A, Messina C, Gadner H, Schrappe M. Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study. Lancet. 2005 Aug 20-26;366(9486):635-42. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
#MRC UKALL XII/ECOG E2993: Rowe JM, Buck G, Burnett AK, Chopra R, Wiernik PH, Richards SM, Lazarus HM, Franklin IM, Litzow MR, Ciobanu N, Prentice HG, Durrant J, Tallman MS, Goldstone AH; ECOG; MRC/NCRI Adult Leukemia Working Party. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005 Dec 1;106(12):3760-7. Epub 2005 Aug 16. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00002514
##Update: Goldstone AH, Richards SM, Lazarus HM, Tallman MS, Buck G, Fielding AK, Burnett AK, Chopra R, Wiernik PH, Foroni L, Paietta E, Litzow MR, Marks DI, Durrant J, McMillan A, Franklin IM, Luger S, Ciobanu N, Rowe JM. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood. 2008 Feb 15;111(4):1827-33. Epub 2007 Nov 29. link to original article EuroPMC
##Update: Fielding AK, Rowe JM, Richards SM, Buck G, Moorman AV, Durrant IJ, Marks DI, McMillan AK, Litzow MR, Lazarus HM, Foroni L, Dewald G, Franklin IM, Luger SM, Paietta E, Wiernik PH, Tallman MS, Goldstone AH. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. Blood. 2009 May 7;113(19):4489-96. Epub 2009 Feb 24. link to original article link to PMC article EuroPMC
##Update: Fielding AK, Rowe JM, Buck G, Foroni L, Gerrard G, Litzow MR, Lazarus H, Luger SM, Marks DI, McMillan AK, Moorman AV, Patel B, Paietta E, Tallman MS, Goldstone AH. UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood. 2014 Feb 6;123(6):843-50. Epub 2013 Nov 25. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article EuroPMC
#ALL-SCT-BFM-2003: Peters C, Schrappe M, von Stackelberg A, Schrauder A, Bader P, Ebell W, Lang P, Sykora KW, Schrum J, Kremens B, Ehlert K, Albert MH, Meisel R, Matthes-Martin S, Gungor T, Holter W, Strahm B, Gruhn B, Schulz A, Woessmann W, Poetschger U, Zimmermann M, Klingebiel T. Stem-cell transplantation in children with acute lymphoblastic leukemia: a prospective international multicenter trial comparing sibling donors with matched unrelated donors-the ALL-SCT-BFM-2003 trial. J Clin Oncol. 2015 Apr 10;33(11):1265-74. Epub 2015 Mar 9. link to original article EuroPMC NCT01423747
#FORUM: Peters C, Dalle JH, Locatelli F, Poetschger U, Sedlacek P, Buechner J, Shaw PJ, Staciuk R, Ifversen M, Pichler H, Vettenranta K, Svec P, Aleinikova O, Stein J, Güngör T, Toporski J, Truong TH, Diaz-de-Heredia C, Bierings M, Ariffin H, Essa M, Burkhardt B, Schultz K, Meisel R, Lankester A, Ansari M, Schrappe M, von Stackelberg A, Balduzzi A, Corbacioglu S, Bader P; IBFM Study Group; IntReALL Study Group; I-BFM SCT Study Group; EBMT Paediatric Diseases Working Party. Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study. J Clin Oncol. 2021 Feb 1;39(4):295-307. Epub 2020 Dec 17. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article EuroPMC NCT01949129
==Fludarabine, Busulfan, Cyclophosphamide==
FluBuCy: Fludarabine, Busulfan, Cyclophosphamide
===Regimen variant #1, oral===
Study 	Dates of enrollment 	Evidence
Glass et al. 2014 (DSHNHL R3)	2004-06-16 to 2009-03-24	Phase 2
This is described by the authors as a lymphoma-directed myeloablative conditioning regimen
====Chemotherapy====
*Fludarabine (Fludara) 25 mg/m2/day IV on days -8 to -4
*Busulfan (Myleran) 4 mg/kg/day PO on days -6 to -4
*Cyclophosphamide (Cytoxan) 60 mg/kg/day IV on days -3 and -2
====Immunotherapy====
*Allogeneic stem cells transfused on day 0
====GVHD prophylaxis====
*Antithymocyte globulin, rabbit ATG (Thymoglobulin) 2 mg/kg IV from day -3 to -1 (unclear if this is a total dose or a daily dose)
**Option also to use ATG-Fresenius S at a higher dose of 10 mg/kg
*Tacrolimus (Prograf) 8 to 12 mcg/L (route/frequency not specified) starting on day -1, tapered from day +100 in absence of GVHD
*Mycophenolate mofetil (CellCept) 1000 mg (route not specified) twice per day from day +1 to +28
One course
===Regimen variant #2, intravenous===
Study 	Dates of enrollment 	Evidence
Glass et al. 2014 (DSHNHL R3)	2004-06-16 to 2009-03-24	Phase 2
This is described by the authors as a lymphoma-directed myeloablative conditioning regimen
====Chemotherapy====
*Fludarabine (Fludara) 25 mg/m2/day IV on days -8 to -4
*Busulfan (Myleran) 3.2 mg/kg/day IV on days -6 to -4
*Cyclophosphamide (Cytoxan) 60 mg/kg/day IV on days -3 and -2
====Immunotherapy====
*Allogeneic stem cells transfused on day 0
====GVHD prophylaxis====
*Antithymocyte globulin, rabbit ATG (Thymoglobulin) 2 mg/kg IV from day -3 to -1 (unclear if this is a total dose or a daily dose)
**Option also to use ATG-Fresenius S at a higher dose of 10 mg/kg
*Tacrolimus (Prograf) 8 to 12 mcg/L (route/frequency not specified) starting on day -1, tapered from day +100 in absence of GVHD
*Mycophenolate mofetil (CellCept) 1000 mg (route not specified) twice per day from day +1 to +28
One course
===References===
#DSHNHL R3: Glass B, Hasenkamp J, Wulf G, Dreger P, Pfreundschuh M, Gramatzki M, Silling G, Wilhelm C, Zeis M, Görlitz A, Pfeiffer S, Hilgers R, Truemper L, Schmitz N; German High-Grade Lymphoma Study Group. Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial. Lancet Oncol. 2014 Jun;15(7):757-66. Epub 2014 May 11. link to original article link to original protocol (in German) dosing details in manuscript have been reviewed by our editors EuroPMC NCT00785330
==Fludarabine & TBI for haploidentical transplant==
Flu/TBI: Fludarabine and Total Body Irradiation
===Regimen===
Study 	Dates of enrollment	Evidence
Soloman et al. 2014	2012-04 to 2014-05 	Phase 2
====Chemotherapy====
*Fludarabine (Fludara) 30 mg/m2/day IV on days -7 to -5 (3 consecutive days)
====Radiotherapy====
*Total body irradiation 150 cGy twice per day on days -4 to -1 (total dose: 1200 cGy)
====Immunotherapy====
*Allogeneic stem cells transfused on day 0
====GVHD prophylaxis====
*Cyclophosphamide (Cytoxan) 50 mg/kg IBW IV over 1 to 2 hours once per day on days +3 & +4, started 60 to 72 hours after marrow infusion
*Mycophenolate mofetil (CellCept) 15 mg/kg (maximum daily dose of 3000 mg; route not specified) every 8 hours, starting on day +5, continued until day +35 or longer at physician discretion if active GVHD was present
*Tacrolimus (Prograf) (route not specified) with a goal trough level of 5 to 10 ng/mL, starting on day +5, continued until day +180
One course
===References===
#Solomon SR, Sizemore CA, Sanacore M, Zhang X, Brown S, Holland HK, Morris LE, Bashey A. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors. Biol Blood Marrow Transplant. 2015 Jul;21(7):1299-307. Epub 2015 Mar 19. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
==BEAM==
BEAM: BCNU (Carmustine), Etoposide, Ara-C (Cytarabine), Melphalan
===Regimen variant #1===
Study 	Dates of enrollment	Evidence
Przepiorka et al. 1999	Not reported 	Phase 2
====Chemotherapy====
*Carmustine (BCNU) 300 mg/m2 IV once on day -6
*Etoposide (Vepesid) 200 mg/m2 IV twice per day on days -5 to -2
*Cytarabine (Ara-C) 200 mg/m2 IV twice per day on days -5 to -2
*Melphalan (Alkeran) 140 mg/m2 IV once on day -1
====Immunotherapy====
*Allogeneic stem cells transfused on day 0
====GVHD prophylaxis====
*Tacrolimus (Prograf) (dose/route not specified)
*Methotrexate (MTX) by the following criteria:
**Marrow recipients: 5 mg/m2 IV once per day on days +1, +3, +6, +11
**Blood stem-cell recipients: 5 mg/m2 IV once per day on days +1, +3, +6
====Supportive therapy====
*"Prophylactic antibiotics"
*Filgrastim (Neupogen) 5 mcg/kg SC once per day, starting on day +7 and continued until engraftment
One course
===Regimen variant #2, attenuated===
Study 	Dates of enrollment	Evidence
Sobol et al. 2013	2000-05 to 2012-04 	Phase 2
====Chemotherapy====
*Carmustine (BCNU) 300 mg/m2 IV once on day -6
*Etoposide (Vepesid) 100 mg/m2 IV once per day on days -5 to -2
*Cytarabine (Ara-C) 100 mg/m2 IV twice per day on days -5 to -2
*Melphalan (Alkeran) 140 mg/m2 IV once on day -1
====Immunotherapy====
*Allogeneic stem cells transfused on day 0
====GVHD prophylaxis====
*Tacrolimus (Prograf) 0.03 mg/kg/day IV continuous infusion, started on day -2
*Methotrexate (MTX) 15 mg/m2 (route not specified) once per day on days +1, +3, +6
One course
====Dose and schedule modifications====
*Tacrolimus titrated to serum level 10 to 15 ng/mL
===References===
#Przepiorka D, van Besien K, Khouri I, Hagemeister F, Samuels B, Folloder J, Ueno NT, Molldrem J, Mehra R, Körbling M, Giralt S, Gajewski J, Donato M, Cleary K, Claxton D, Braunschweig I, Andersson B, Anderlini P, Champlin R. Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. Ann Oncol. 1999 May;10(5):527-32. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
#Sobol U, Rodriguez T, Smith S, Go A, Vimr R, Parthasarathy M, Guo R, Stiff P. Seven-year follow-up of allogeneic transplant using BCNU, etoposide, cytarabine and melphalan chemotherapy in patients with Hodgkin lymphoma after autograft failure: importance of minimal residual disease. Leuk Lymphoma. 2014 Jun;55(6):1281-7. Epub 2013 Oct 3. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
==BFR==
BFR: Bendamustine, Fludarabine, Rituximab
===Regimen===
Study 	Dates of enrollment	Evidence
Khouri et al. 2014 (MDACC 2008-0246)	2009-04 to 2013-02 	Phase 2
====Chemotherapy====
*Bendamustine 130 mg/m2 IV once per day on days -5 to -3
*Fludarabine (Fludara) 30 mg/m2 IV over 30 minutes once per day on days -5 to -3
====Targeted therapy====
*Rituximab (Rituxan) 375 mg/m2 IV once per day on days -13, -6, +1, +8
====Immunotherapy====
*Allogeneic stem cells transfused on day 0
====GVHD prophylaxis====
*See article for GVHD prophylaxis information
One course
===References===
#MDACC 2008-0246: Khouri IF, Wei W, Korbling M, Turturro F, Ahmed S, Alousi A, Anderlini P, Ciurea S, Jabbour E, Oran B, Popat UR, Rondon G, Bassett RL Jr, Gulbis A. BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD. Blood. 2014 Oct 2;124(14):2306-12. Epub 2014 Aug 21. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article EuroPMC NCT00880815
=Reduced-intensity conditioning (RIC), all lines of therapy=
==Busulfan & Fludarabine==
BuFlu: Busulfan & Fludarabine
Flu/Bu: Fludarabine & Busulfan
===Regimen variant #1, 90/6.4===
Study 	Dates of enrollment 	Evidence 	Comparator 	Comparative Efficacy
de Masson et al. 2023 (CUTALLO)	2016-06-01 to 2022-03-03	Propensity score analysis (E-esc)	No transplant	Longer PFS (primary endpoint)Median PFS: 9 vs 3 mo(HR 0.38, 95% CI 0.21-0.69)
Diseases Studied: Cutaneous T-cell lymphoma
====Chemotherapy====
*Fludarabine (Fludara) 30 mg/m2 IV once per day for 3 days (days not specified)
*Busulfan (Myleran) 3.2 mg/kg/day IV for 2 days (days not specified)
====Immunotherapy====
*Allogeneic stem cells transfused on day 0
====GVHD prophylaxis====
*Cyclosporine started on day -1, tapered on day +90 if no GVHD
*Methotrexate (MTX) 15 mg/m2 IV once on day +1, then 10 mg/m2 IV once per day on days +3, +6, +11
One course
===Regimen variant #2, 125/4===
Study 	Dates of enrollment	Evidence
Garban et al. 2006 (IFM99-03)	2000-04 to 2004-09 	Non-randomized
This regimen was meant for patients who had an HLA-identical sibling donor, and was evaluated in multiple myeloma patients.
====Chemotherapy====
*Fludarabine (Fludara) 25 mg/m2/day (route not specified) for 5 days (days not specified)
*Busulfan (Myleran) 2 mg/kg PO once per day for 2 days (days not specified)
====Immunotherapy====
*Allogeneic stem cells transfused on day 0
====GVHD prophylaxis====
*ATG, rabbit (Imtix) 2.5 mg/kg IV over 12 hours once per day on days -5 to -1
*Cyclosporine 3 mg/kg/day (route not specified), starting on day -1 
*Methotrexate (MTX) 10 mg/m2 (route not specified) once per day on days +1, +3, +6
One course
====Dose and schedule modifications====
*Cyclosporine doses adjusted to "serum levels", tapered on day +60 to off by day +100 (if no GVHD)
===Regimen variant #3, 150/6.4===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Devine et al. 2015 (CALGB 100103) 	2004-2011 	Phase 2 	 	
Beelen et al. 2019 (MC-FludT.14/L)	2013-2016 	Phase 3 (C)	Fludarabine & Treosulfan	Non-inferior EFS24
This regimen is meant for related donors; in CALGB 100103, 8 patients received this regimen before the addition of ATG (rabbit) after 2006.
====Chemotherapy====
*Fludarabine (Fludara) 30 mg/m2 IV over 30 minutes once per day on days -7 to -3
**MC-FludT.14/L gave the doses on days -6 to -2
*Busulfan (Myleran) 0.8 mg/kg IV over 2 hours every 6 hours on days -4 & -3 (total dose: 6.4 mg/kg)
====Immunotherapy====
*Allogeneic stem cells transfused on day 0
====GVHD prophylaxis====
*ATG (Rabbit) 2.5 mg/kg IV over 6 hours once per day on days -4 to -2
*Tacrolimus (Prograf) with doses adjusted to maintain levels of 5 to 10 ng/mL, tapered on day +90 to off by day +180 (if no GVHD)
*Methotrexate (MTX) 5 mg/m2 IV once per day on days +1, +3, +6, +11
One course
===Regimen variant #4, 150/360===
Study 	Dates of enrollment	Evidence
Mohty et al. 2014 (ITT 08-01)	2009-2011 	Phase 2
====Chemotherapy====
*Fludarabine (Fludara) 30 mg/m2/day (route not specified) on days -6 to -2
*Busulfan (Myleran) 130 mg/m2 IV over 3 hours once per day on days -5 to -3
====GVHD prophylaxis====
*Antithymocyte globulin (ATG) (source not specified) 2.5 mg/kg/day IV on days -2 & -1
*As per Mohty et al. 2003
====Immunotherapy====
*Allogeneic stem cells transfused on day 0
One course
===Regimen variant #5, 180/8===
Study 	Evidence
Slavin et al. 1998 	Phase 2
Schetelig et al. 2003	Phase 2
====Chemotherapy====
*Fludarabine (Fludara) 30 mg/m2 IV once per day on days -10 to -5 (6 consecutive days)
*Busulfan (Myleran) 4 mg/kg/day PO on days -6 to -5 (2 consecutive days)
====GVHD prophylaxis====
*ATG-Fresenius 10 mg/kg IV once per day on days -4 to -1 (4 consecutive days)
====Immunotherapy====
*Allogeneic stem cells transfused on day 0
One course
===References===
#Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Amar A, Brautbar C, Ben-Tal O, Eldor A, Or R. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998 Feb 1;91(3):756-63. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
#Schetelig J, Thiede C, Bornhauser M, Schwerdtfeger R, Kiehl M, Beyer J, Sayer HG, Kroger N, Hensel M, Scheffold C, Held TK, Hoffken K, Ho AD, Kienast J, Neubauer A, Zander AR, Fauser AA, Ehninger G, Siegert W; Cooperative German Transplant Study Group. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol. 2003 Jul 15;21(14):2747-53. link to original article contains reference to protocol EuroPMC
#IFM99-03: Garban F, Attal M, Michallet M, Hulin C, Bourhis JH, Yakoub-Agha I, Lamy T, Marit G, Maloisel F, Berthou C, Dib M, Caillot D, Deprijck B, Ketterer N, Harousseau JL, Sotto JJ, Moreau P. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood. 2006 May 1;107(9):3474-80. Epub 2006 Jan 5. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
##Pooled update: Moreau P, Garban F, Attal M, Michallet M, Marit G, Hulin C, Benboubker L, Doyen C, Mohty M, Yakoub-Agha I, Leyvraz S, Casassus P, Avet-Loiseau H, Garderet L, Mathiot C, Harousseau JL; IFM. Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma. Blood. 2008 Nov 1;112(9):3914-5. link to original article EuroPMC
#ITT 08-01: Mohty M, Malard F, Blaise D, Milpied N, Furst S, Tabrizi R, Guillaume T, Vigouroux S, El-Cheikh J, Delaunay J, Le Gouill S, Moreau P, Labopin M, Chevallier P. Reduced-toxicity conditioning with fludarabine, once-daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: results of a multicenter prospective phase 2 trial. Cancer. 2015 Feb 15;121(4):562-9. Epub 2014 Oct 3. Erratum in: Cancer. 2015 Mar 1;121(5):800. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00841724
#CALGB 100103: Devine SM, Owzar K, Blum W, Mulkey F, Stone RM, Hsu JW, Champlin RE, Chen YB, Vij R, Slack J, Soiffer RJ, Larson RA, Shea TC, Hars V, Sibley AB, Giralt S, Carter S, Horowitz MM, Linker C, Alyea EP. Phase II study of allogeneic transplantation for older patients with acute myeloid leukemia in first complete remission using a reduced-intensity conditioning regimen: results from Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. J Clin Oncol. 2015 Dec 10;33(35):4167-75. Epub 2015 Nov 2. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article EuroPMC NCT00070135
#MC-FludT.14/L: Beelen DW, Trenschel R, Stelljes M, Groth C, Masszi T, Reményi P, Wagner-Drouet EM, Hauptrock B, Dreger P, Luft T, Bethge W, Vogel W, Ciceri F, Peccatori J, Stölzel F, Schetelig J, Junghanß C, Grosse-Thie C, Michallet M, Labussiere-Wallet H, Schaefer-Eckart K, Dressler S, Grigoleit GU, Mielke S, Scheid C, Holtick U, Patriarca F, Medeot M, Rambaldi A, Micò MC, Niederwieser D, Franke GN, Hilgendorf I, Winkelmann NR, Russo D, Socié G, Peffault de Latour R, Holler E, Wolff D, Glass B, Casper J, Wulf G, Menzel H, Basara N, Bieniaszewska M, Stuhler G, Verbeek M, Grass S, Iori AP, Finke J, Benedetti F, Pichlmeier U, Hemmelmann C, Tribanek M, Klein A, Mylius HA, Baumgart J, Dzierzak-Mietla M, Markiewicz M. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial. Lancet Haematol. 2020 Jan;7(1):e28-e39. Epub 2019 Oct 9. link to original article dosing details in abstract have been reviewed by our editors EuroPMC NCT00822393
#CUTALLO: de Masson A, Beylot-Barry M, Ram-Wolff C, Mear JB, Dalle S, d'Incan M, Ingen-Housz-Oro S, Orvain C, Abraham J, Dereure O, Charbonnier A, Cornillon J, Longvert C, Barete S, Boulinguez S, Wierzbicka-Hainaut E, Aubin F, Rubio MT, Bernard M, Schmidt-Tanguy A, Houot R, Pham-Ledard A, Michonneau D, Brice P, Labussière-Wallet H, Bouaziz JD, Grange F, Moins-Teisserenc H, Jondeau K, Michel L, Mourah S, Battistella M, Daguindau E, Loschi M, Picard A, Franck N, Maillard N, Huynh A, Nguyen S, Marçais A, Chaby G, Ceballos P, Le Corre Y, Maury S, Bay JO, Adamski H, Bachy E, Forcade E, Socié G, Bagot M, Chevret S, Peffault de Latour R; CUTALLO Investigators; Groupe Français d'Etude des Lymphomes Cutanés; Société Française de Greffe de Moëlle et Thérapie Cellulaire. Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study. Lancet. 2023 Jun 10;401(10392):1941-1950. Epub 2023 Apr 24. link to original article dosing details in supplement have been reviewed by our editors EuroPMC NCT02520908
==Busulfan, Fludarabine, Ibritumomab tiuxetan==
===Regimen===
Study 	Evidence
Bouabdallah et al. 2015 (ZEVALLO)	Phase 2
====Chemotherapy====
*Fludarabine (Fludara) 30 mg/m2 IV once per day on days -6 to -2
*Busulfan (Myleran) 3.2 mg/kg/day (route not specified) on days -5 & -4
====Targeted therapy====
*Rituximab (Rituxan) 250 mg/m2 IV once per day on days -21 & -14
====Radioconjugate therapy====
*Ibritumomab tiuxetan (Zevalin) 0.4 mCi/kg (maximum dose of 32 mCi) IV once on day -14
====Immunotherapy====
*Allogeneic stem cells transfused on day 0
====GVHD prophylaxis====
*Antithymocyte globulin, rabbit ATG (Thymoglobulin) 2.5 mg/kg IV once on day -1
*Cyclosporine (dose not specified) until day +90 and tapered off by day +180 based on chimerism and GVHD
*Methotrexate (MTX) by the following donor-based criteria:
**Unrelated donors with HLA mismatch: 15 mg/m2 (route not specified) once on day +1, then 10 mg/m2 (route not specified) once per day on days +3 & +6
One course
===References===
#ZEVALLO: Bouabdallah K, Furst S, Asselineau J, Chevalier P, Tournilhac O, Ceballos P, Vigouroux S, Tabrizi R, Doussau A, Bouabdallah R, Mohty M, Le Gouill S, Blaise D, Milpied N. 90Y-ibritumomab tiuxetan, fludarabine, busulfan and antithymocyte globulin reduced-intensity allogeneic transplant conditioning for patients with advanced and high-risk B-cell lymphomas. Ann Oncol. 2015 Jan;26(1):193-8. Epub 2014 Oct 30. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00607854
==Busulfan, Fludarabine, Thiotepa==
===Regimen===
Study 	Dates of enrollment 	Evidence 	Comparator 	Comparative Efficacy
de Masson et al. 2023 (CUTALLO)	2016-06-01 to 2022-03-03	Propensity score analysis (E-esc)	No transplant	Longer PFS (primary endpoint)Median PFS: 9 vs 3 mo(HR 0.38, 95% CI 0.21-0.69)
Diseases Studied: Cutaneous T-cell lymphoma
Note: this preparative regimen was intended for haploidentical HSCT.
====Chemotherapy====
*Fludarabine (Fludara) 50 mg/m2 IV once per day for 3 days (days not specified)
*Busulfan (Myleran) 3.2 mg/kg/day IV for 3 days (days not specified)
*Thiotepa (Tepadina) 5 mg/kg IV once (day not specified)
====Immunotherapy====
*Allogeneic stem cells transfused on day 0
====GVHD prophylaxis====
*Cyclophosphamide (Cytoxan) 50 mg/kg IV once per day on days +3 & +5
*Cyclosporine started on day -1, tapered on day +90 if no GVHD
*Mycophenolate mofetil (CellCept) 15 mg/kg PO three times per day until day +35
One course
===References===
#CUTALLO: de Masson A, Beylot-Barry M, Ram-Wolff C, Mear JB, Dalle S, d'Incan M, Ingen-Housz-Oro S, Orvain C, Abraham J, Dereure O, Charbonnier A, Cornillon J, Longvert C, Barete S, Boulinguez S, Wierzbicka-Hainaut E, Aubin F, Rubio MT, Bernard M, Schmidt-Tanguy A, Houot R, Pham-Ledard A, Michonneau D, Brice P, Labussière-Wallet H, Bouaziz JD, Grange F, Moins-Teisserenc H, Jondeau K, Michel L, Mourah S, Battistella M, Daguindau E, Loschi M, Picard A, Franck N, Maillard N, Huynh A, Nguyen S, Marçais A, Chaby G, Ceballos P, Le Corre Y, Maury S, Bay JO, Adamski H, Bachy E, Forcade E, Socié G, Bagot M, Chevret S, Peffault de Latour R; CUTALLO Investigators; Groupe Français d'Etude des Lymphomes Cutanés; Société Française de Greffe de Moëlle et Thérapie Cellulaire. Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study. Lancet. 2023 Jun 10;401(10392):1941-1950. Epub 2023 Apr 24. link to original article dosing details in supplement have been reviewed by our editors EuroPMC NCT02520908
==Clofarabine & Melphalan==
===Regimen===
Study 	Evidence
Middeke et al. 2015 (BRIDGE)	Phase 2
Note: Limited details were available in the abstract. Treatment was meant to be given during aplasia.
====Preceding treatment====
*Clofarabine & Cytarabine salvage
====Chemotherapy====
*Clofarabine (Clolar) 4 x 30 mg/m2 IV
*Melphalan (Alkeran) 140 mg/m2 IV
====Immunotherapy====
*Allogeneic stem cells transfused on unspecified day
One course
===References===
#BRIDGE: Middeke JM, Herbst R, Parmentier S, Bug G, Hänel M, Stuhler G, Schäfer-Eckart K, Rösler W, Klein S, Bethge W, Bitz U, Büttner B, Knoth H, Alakel N, Schaich M, Morgner A, Kramer M, Sockel K, von Bonin M, Stölzel F, Platzbecker U, Röllig C, Thiede C, Ehninger G, Bornhäuser M, Schetelig J. Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial. Leukemia. 2016 Feb;30(2):261-7. Epub 2015 Aug 18. link to original article dosing details in abstract have been reviewed by our editors EuroPMC
==Cyclophosphamide & Fludarabine (FC)==
FC: Fludarabine & Cyclophosphamide
FluCy: Fludarabine & Cyclophosphamide
===Regimen variant #1, 150/2500===
Study 	Evidence
Dreger et al. 2010 (GCLLSG CLL3X)	Phase 2
====Chemotherapy====
*Fludarabine (Fludara) 30 mg/m2 IV once per day on days -6 to -2 (5 consecutive days)
*Cyclophosphamide (Cytoxan) 500 mg/m2 IV once per day on days -6 to -2 (5 consecutive days)
====GVHD prophylaxis====
*ATG-Fresenius by the following donor-based criteria:
**Unrelated donors: 10 mg/kg/day IV on days -4 to -1 (4 consecutive days)
====Immunotherapy====
*Allogeneic stem cells transfused on day 0
One course
===Regimen variant #2, 125/120===
Study 	Dates of enrollment	Evidence
Childs et al. 2000 (NIH 97-H-0196)	1998-02 to 1999-08 	Non-randomized, fewer than 20 pts
====Chemotherapy====
*Fludarabine (Fludara) 25 mg/m2 IV once per day on days -5 to -1
*Cyclophosphamide (Cytoxan) 60 mg/kg IV once per day on days -7 & -6
====Immunotherapy====
*Allogeneic stem cells transfused on day 0
One course
===References===
#NIH 97-H-0196: Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S, Read EJ, Tisdale J, Dunbar C, Linehan WM, Young NS, Clave E, Epperson D, Mayo V, Barrett AJ. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med. 2000 Sep 14;343(11):750-8. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
#GCLLSG CLL3X: Dreger P, Döhner H, Ritgen M, Böttcher S, Busch R, Dietrich S, Bunjes D, Cohen S, Schubert J, Hegenbart U, Beelen D, Zeis M, Stadler M, Hasenkamp J, Uharek L, Scheid C, Humpe A, Zenz T, Winkler D, Hallek M, Kneba M, Schmitz N, Stilgenbauer S; German CLL Study Group. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood. 2010 Oct 7;116(14):2438-47. Epub 2010 Jul 1. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00281983
##Update: Dreger P, Schnaiter A, Zenz T, Böttcher S, Rossi M, Paschka P, Bühler A, Dietrich S, Busch R, Ritgen M, Bunjes D, Zeis M, Stadler M, Uharek L, Scheid C, Hegenbart U, Hallek M, Kneba M, Schmitz N, Döhner H, Stilgenbauer S. TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial. Blood. 2013 Apr 18;121(16):3284-8. Epub 2013 Feb 22. link to original article EuroPMC
##Update: Krämer I, Stilgenbauer S, Dietrich S, Böttcher S, Zeis M, Stadler M, Bittenbring J, Uharek L, Scheid C, Hegenbart U, Ho A, Hallek M, Kneba M, Schmitz N, Döhner H, Dreger P. Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial. Blood. 2017 Sep 21;130(12):1477-1480. Epub 2017 Jul 17. link to original article EuroPMC
==FBM==
FBM: Fludarabine, BCNU (Carmustine), Melphalan
===Regimen variant #1===
Study 	Dates of enrollment	Evidence
Marks et al. 2008	1998-2003 	Phase 2
Note: this variant was intended for patients younger than 55 years of age.
====Chemotherapy====
*Fludarabine (Fludara) 30 mg/m2 IV once per day on days -9 to -5
*Carmustine (BCNU) 200 mg/m2 IV once per day on days -7 & -6
*Melphalan (Alkeran) 140 mg/m2 IV once on day -4
====Immunotherapy====
*Allogeneic stem cells transfused on day 0
One course
===Regimen variant #2===
Study 	Dates of enrollment	Evidence
Marks et al. 2008	1998-2003 	Phase 2
Note: this variant was intended for patients 55 years of age and older.
====Chemotherapy====
*Fludarabine (Fludara) 30 mg/m2 IV once per day on days -9 to -5
*Carmustine (BCNU) 150 mg/m2 IV once per day on days -7 & -6
*Melphalan (Alkeran) 110 mg/m2 IV once on day -4
====Immunotherapy====
*Allogeneic stem cells transfused on day 0
One course
===References===
#Marks R, Potthoff K, Hahn J, Ihorst G, Bertz H, Spyridonidis A, Holler E, Finke JM. Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies. Blood. 2008 Jul 15;112(2):415-25. Epub 2008 May 1. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
==FCR==
FCR: Fludarabine, Cyclophosphamide, Rituximab
===Regimen===
Study 	Dates of enrollment	Evidence
Khouri et al. 2001 (MDACC ID01-233)	1997-2000 	Phase 2
Details are best described in the 2008 update.
====Chemotherapy====
*Fludarabine (Fludara) 30 mg/m2 IV once per day on days -5 to -3
*Cyclophosphamide (Cytoxan) 750 mg/m2 IV once per day on days -5 to -3
====Targeted therapy====
*Rituximab (Rituxan) 375 mg/m2 IV once on day -13, then 1000 mg/m2 IV once per day on days -6, +1, +8
====Immunotherapy====
*Allogeneic stem cells transfused on day 0
====GVHD prophylaxis====
*Antithymocyte globulin, horse ATG (Atgam) by the following donor-based criteria:
**Matched unrelated donor: 15 mg/kg IV once per day on days -5 to -3
*Tacrolimus (Prograf) adjusted to level of 5 to 10 ng/mL for 6 months in patients in remission
*Methotrexate (MTX) by the following donor-based criteria:
**Related donors: 5 mg/m2 IV once per day on days +1, +3, +6
**Unrelated donors: 5 mg/m2 IV once per day on days +1, +3, +6, +11
One course
===References===
#MDACC ID01-233: Khouri IF, Saliba RM, Giralt SA, Lee MS, Okoroji GJ, Hagemeister FB, Korbling M, Younes A, Ippoliti C, Gajewski JL, McLaughlin P, Anderlini P, Donato ML, Cabanillas FF, Champlin RE. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood. 2001 Dec 15;98(13):3595-9. link to original article EuroPMC NCT00048737
##Update: Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS, Medeiros LJ, Fayad L, Samaniego F, Alousi A, Anderlini P, Couriel D, de Lima M, Giralt S, Neelapu SS, Ueno NT, Samuels BI, Hagemeister F, Kwak LW, Champlin RE. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood. 2008 Jun 15;111(12):5530-6. Epub 2008 Apr 14. Erratum in: Blood. 2009 Feb 12;113(7):1613. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article EuroPMC
##Update: Khouri IF, Saliba RM, Erwin WD, Samuels BI, Korbling M, Medeiros LJ, Valverde R, Alousi AM, Anderlini P, Bashir Q, Ciurea S, Gulbis AM, de Lima M, Hosing C, Kebriaei P, Popat UR, Fowler N, Neelapu SS, Samaniego F, Champlin RE, Macapinlac HA. Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood. 2012 Jun 28;119(26):6373-8. Epub 2012 May 14. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article EuroPMC
==Fludarabine & TBI==
===Regimen variant #1===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy 	Non-relapse mortality
Bornhäuser et al. 2012 (9005-2003)	2004-2009 	Phase 3 (E-switch-ic)	Cyclophosphamide & TBI	Did not meet secondary efficacy endpoints	Did not meet primary endpoint of NRM
====Chemotherapy====
*Fludarabine (Fludara) 30 mg/m2 IV once per day on days -6 to -3
====Radiotherapy====
*Total body irradiation (TBI) 200 cGy fractions x 4 doses on days -3 & -2 (800 cGy total)
====Immunotherapy====
*Allogeneic stem cells transfused on day 0
One course
===Regimen variant #2, low-dose TBI===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Sorror et al. 2005 	1997-2003 	Phase 2 	 	
Gyukocza et al. 2010 	1998-2008 	Non-randomized 	 	
Maris et al. 2003 	2000-2001 	Phase 2 	 	
Björkstrand et al. 2011 (EBMT-NMAM2000)	2001-2005 	Non-randomized part of RCT	 	
Kornblit et al. 2013 (FHCRC 1813.00) 	2003-2011 	Phase 3 (E-esc) 	Low-dose TBI	Might have higher OS36 (primary endpoint)
Details are best described in Maris et al. 2003.
====Chemotherapy====
*Fludarabine (Fludara) 30 mg/m2 IV once per day on days -4 to -2
====Radiotherapy====
*Total body irradiation (TBI) 200 cGy at a rate of 7 cGy/min on day 0
====Immunotherapy====
*Allogeneic stem cells transfused on day 0
====GVHD prophylaxis====
*Cyclosporine 6.25 mg/kg PO twice per day starting 4 to 6 hours after transplant, tapered at day 100 over 80 days (if no GVHD)
*Mycophenolate mofetil (CellCept) 15 mg/kg PO twice per day starting 4 to 6 hours after transplant, tapered at day 40 over 56 days (if no GVHD)
One course
===References===
#Maris MB, Niederwieser D, Sandmaier BM, Storer B, Stuart M, Maloney D, Petersdorf E, McSweeney P, Pulsipher M, Woolfrey A, Chauncey T, Agura E, Heimfeld S, Slattery J, Hegenbart U, Anasetti C, Blume K, Storb R. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood. 2003 Sep 15;102(6):2021-30. Epub 2003 Jun 5. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
#Sorror ML, Maris MB, Sandmaier BM, Storer BE, Stuart MJ, Hegenbart U, Agura E, Chauncey TR, Leis J, Pulsipher M, McSweeney P, Radich JP, Bredeson C, Bruno B, Langston A, Loken MR, Al-Ali H, Blume KG, Storb R, Maloney DG. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol. 2005 Jun 1;23(16):3819-29. Epub 2005 Apr 4. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
##Update: Sorror ML, Storer BE, Sandmaier BM, Maris M, Shizuru J, Maziarz R, Agura E, Chauncey TR, Pulsipher MA, McSweeney PA, Wade JC, Bruno B, Langston A, Radich J, Niederwieser D, Blume KG, Storb R, Maloney DG. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol. 2008 Oct 20;26(30):4912-20. Epub 2008 Sep 15. link to original article link to PMC article EuroPMC
#Gyurkocza B, Storb R, Storer BE, Chauncey TR, Lange T, Shizuru JA, Langston AA, Pulsipher MA, Bredeson CN, Maziarz RT, Bruno B, Petersen FB, Maris MB, Agura E, Yeager A, Bethge W, Sahebi F, Appelbaum FR, Maloney DG, Sandmaier BM. Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. J Clin Oncol. 2010 Jun 10;28(17):2859-67. Epub 2010 May 3. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article EuroPMC
#EBMT-NMAM2000: Björkstrand B, Iacobelli S, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Musto P, Beksac M, Bosi A, Milone G, Corradini P, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Gahrton G. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. J Clin Oncol. 2011 Aug 1;29(22):3016-22. Epub 2011 Jul 5. Erratum in: J Clin Oncol. 2011 Sep 20;29(27):3721. link to original article dosing details in abstract have been reviewed by our editors EuroPMC
##Update: Gahrton G, Iacobelli S, Björkstrand B, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Carella AM, Beksac M, Bosi A, Milone G, Corradini P, Schönland S, Friberg K, van Biezen A, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Garderet L, Kröger N; EBMT Chronic Malignancies Working Party Plasma Cell Disorders Subcommittee. Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. Blood. 2013 Jun 20;121(25):5055-63. Epub 2013 Mar 12. link to original article EuroPMC
#9005-2003: Bornhäuser M, Kienast J, Trenschel R, Burchert A, Hegenbart U, Stadler M, Baurmann H, Schäfer-Eckart K, Holler E, Kröger N, Schmid C, Einsele H, Kiehl MG, Hiddemann W, Schwerdtfeger R, Buchholz S, Dreger P, Neubauer A, Berdel WE, Ehninger G, Beelen DW, Schetelig J, Stelljes M. Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. Lancet Oncol. 2012 Oct;13(10):1035-44. Epub 2012 Sep 7. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00150878
#FHCRC 1813.00: Kornblit B, Maloney DG, Storb R, Storek J, Hari P, Vucinic V, Maziarz RT, Chauncey TR, Pulsipher MA, Bruno B, Petersen FB, Bethge WA, Hübel K, Bouvier ME, Fukuda T, Storer BE, Sandmaier BM. Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trial. Biol Blood Marrow Transplant. 2013 Sep;19(9):1340-7. Epub 2013 Jun 11. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00075478
#Niederwieser D, Hasenclever D, Berdel WE, Biemond BJ, Al-Ali H, Chalandon Y, Van Gelder M, Junghanß C, Gahrton G, Hänel M, Hehlmann R, Heinicke T, Hochhaus A, Iacobelli S, Kooy RVM, Kröger N, Janssen J, Jentzsch M, Breywisch F, Mohty M, Masouridi-Levrat S, Ossenkoppele G, Passweg J, Pönisch W, Schetelig J, Schliemann C, Schwind S, Stelljes M, Verdonck LF, Vucinic V, Löwenberg B, Cornelissen J. Hematopoietic cell transplantation for older acute myeloid leukemia patients in first complete remission: results of a randomized phase III study. Haematologica. 2025 Jan 1;110(1):68-77. link to original article link to PMC article EuroPMC EudraCT 2007-003514-34
==Fludarabine, Cyclophosphamide, TBI for dUCB or haploidentical transplant==
dUCB: double Umbilical Cord Blood
===Regimen variant #1, dUCB transplantation===
Study 	Dates of enrollment	Evidence
Brunstein et al. 2011 (BMT CTN 0604)	2009-01 to 2010-03 	Phase 2
====Chemotherapy====
*Fludarabine (Fludara) 40 mg/m2 IV once per day on days -6 to -2 (5 consecutive days)
*Cyclophosphamide (Cytoxan) 50 mg/kg IV once on day -6
====Radiotherapy====
*Total body irradiation (TBI) 200 cGy once on day -1
====Immunotherapy====
*Allogeneic stem cells transfused on day 0
====Supportive therapy====
*Mesna (Mesnex) (dose/route/schedule not specified) and "vigorous IV hydration for uroprotection."
*Filgrastim (Neupogen) 5 mcg/kg SC once per day, starting on day +1, continued until ANC greater than or equal to 2000/μL for 3 consecutive days
====GVHD prophylaxis====
*Mycophenolate mofetil (CellCept) by the following weight-based criteria:
**More than 50 kg: 1000 mg (route not specified) every 8 hours, starting on day -3 "and continuing until day +30 or 7 days after engraftment, whichever was later"
**Less than 50 kg: 15 mg/kg (route not specified) every 8 hours, starting on day -3 "and continuing until day +30 or 7 days after engraftment, whichever was later"
*Cyclosporine (route not specified) with a goal trough of 200 to 400 ng/mL (starting date not specified) until day +100. Patients without GVHD had their dose tapered by 10% each week starting on day +101, with discontinuation of cyclosporine A around day +180 to +200.
*Tacrolimus (Prograf) (route not specified) with a goal trough level of 5 to 10 ng/mL could be substituted for cyclosporine.
One course
===Regimen variant #2, Haploidentical===
Study 	Dates of enrollment	Evidence
Brunstein et al. 2011 (BMT CTN 0603)	2009-01 to 2010-03 	Phase 2
====Chemotherapy====
*Fludarabine (Fludara) 30 mg/m2 IV once per day on days -6 to -2 (5 consecutive days)
*Cyclophosphamide (Cytoxan) 14.5 mg/kg IV once per day on days -6 and -5 (2 consecutive days)
====Radiotherapy====
*Total body irradiation (TBI) 200 cGy once on day -1
====Immunotherapy====
*Allogeneic stem cells transfused on day 0
====Supportive therapy====
*Mesna (Mesnex) (dose/route/schedule not specified) and "vigorous IV hydration for uroprotection."
*Filgrastim (Neupogen) 5 mcg/kg SC once per day, starting on day +5, continued until ANC greater than or equal to 1000/μL for 3 consecutive days
====GVHD prophylaxis====
*Cyclophosphamide (Cytoxan) 50 mg/kg IBW IV over 1 to 2 hours once per day on days +3 & +4, started 60 to 72 hours after marrow infusion
*Mycophenolate mofetil (CellCept) 15 mg/kg (maximum daily dose of 3000 mg; route not specified) every 8 hours, starting on day +5, continued until day +35 or longer at physician discretion if active GVHD was present
*Tacrolimus (Prograf) (route not specified) with a goal trough level of 5 to 10 ng/mL, starting on day +5, continued until day +180
One course
===References===
#BMT CTN 0603: Brunstein CG, Fuchs EJ, Carter SL, Karanes C, Costa LJ, Wu J, Devine SM, Wingard JR, Aljitawi OS, Cutler CS, Jagasia MH, Ballen KK, Eapen M, O'Donnell PV; BMT CTN. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood. 2011 Jul 14;118(2):282-8. Epub 2011 Apr 28. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article EuroPMC NCT00849147
#BMT CTN 0604: Brunstein CG, Fuchs EJ, Carter SL, Karanes C, Costa LJ, Wu J, Devine SM, Wingard JR, Aljitawi OS, Cutler CS, Jagasia MH, Ballen KK, Eapen M, O'Donnell PV; BMT CTN. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood. 2011 Jul 14;118(2):282-8. Epub 2011 Apr 28. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article EuroPMC NCT00864227
#BMT CTN 0501: Wagner JE Jr, Eapen M, Carter S, Wang Y, Schultz KR, Wall DA, Bunin N, Delaney C, Haut P, Margolis D, Peres E, Verneris MR, Walters M, Horowitz MM, Kurtzberg J; Blood and Marrow Transplant Clinical Trials Network. One-unit versus two-unit cord-blood transplantation for hematologic cancers. N Engl J Med. 2014 Oct 30;371(18):1685-94. link to original article link to PMC article EuroPMC NCT00412360
#BMT CTN 1101: Fuchs EJ, O'Donnell PV, Eapen M, Logan B, Antin JH, Dawson P, Devine S, Horowitz MM, Horwitz ME, Karanes C, Leifer E, Magenau JM, McGuirk JP, Morris LE, Rezvani AR, Jones RJ, Brunstein CG. Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial. Blood. 2021 Jan 21;137(3):420-428. link to original article link to PMC article EuroPMC NCT01597778
##HRQoL analysis: El Jurdi N, Martens MJ, Brunstein CG, O'Donnell P, Lee SJ, D'Souza A, Logan B, Hong S, Singh AK, Sandhu K, Shapiro RM, Horowitz MM, Hamilton BK. Health-Related Quality of Life in Double Umbilical Cord Blood versus Haploidentical Marrow Transplantation: A Quality of Life Analysis Report of BMT CTN 1101. Transplant Cell Ther. 2023 Jul;29(7):467.e1-467.e5. Epub 2023 Apr 22. link to original article link to PMC article EuroPMC
==Fludarabine & Melphalan==
Flu-Mel: Fludarabine & Melphalan
===Regimen variant #1, 90/140===
Study 	Dates of enrollment 	Evidence 	Comparator 	Comparative Efficacy
de Masson et al. 2023 (CUTALLO)	2016-06-01 to 2022-03-03	Propensity score analysis (E-esc)	No transplant	Longer PFS (primary endpoint)Median PFS: 9 vs 3 mo(HR 0.38, 95% CI 0.21-0.69)
Diseases Studied: Cutaneous T-cell lymphoma
====Chemotherapy====
*Fludarabine (Fludara) 30 mg/m2 IV once per day for 3 days (days not specified)
*Melphalan (Alkeran) 140 mg/m2 IV once (day not specified)
====Immunotherapy====
*Allogeneic stem cells transfused on day 0
====GVHD prophylaxis====
*Cyclosporine started on day -1, tapered on day +90 if no GVHD
*Methotrexate (MTX) 15 mg/m2 IV once on day +1, then 10 mg/m2 IV once per day on days +3, +6, +11
One course
===Regimen variant #2, 132/140===
Study 	Dates of enrollment	Evidence
Anderlini et al. 2008	2001-2005 	Phase 2
Diseases Studied: Classical Hodgkin lymphoma
====Chemotherapy====
*Fludarabine (Fludara) 33 mg/m2 IV once per day on days -5 to -2
*Melphalan (Alkeran) 70 mg/m2 IV once per day on days -3 & -2
====Immunotherapy====
*Allogeneic stem cells transfused on day 0
====GVHD prophylaxis====
*ATG (type not specified) by the following donor-based criteria:
**Matched unrelated donor: 2 mg/kg IV once per day on days -4 to -2
*Tacrolimus (Prograf) IV starting on day -2, switched to PO as soon as possible. Continued for at least 6 months and then "tapered off" (instructions not given).
*Methotrexate (MTX) 5 mg/m2 IV once per day on days +1, +3, +6 (extra dose on day +11 for MUD recipients)
One course
====Dose and schedule modifications====
*Tacrolimus dosed to achieve serum levels 4 to 12 ng/mL
===Regimen variant #3, 150/140===
Study 	Dates of enrollment	Evidence
Alvarez et al. 2006 	1999-06 to 2004-01 	Prospective
Sureda et al. 2011 (HDR-ALLO)	Not reported 	Phase 2
Diseases Studied: Classical Hodgkin lymphoma
Note: Alvarez et al. 2006 began CsA on day -1 and did not give day +11 MTX.
====Chemotherapy====
*Fludarabine (Fludara) 30 mg/m2 IV once per day on days -8 to -4
*Melphalan (Alkeran) 70 mg/m2 IV once per day on days -3 & -2
====Immunotherapy====
*Allogeneic stem cells transfused on day 0
====GVHD prophylaxis====
*Recipients of stem cells from matched unrelated donors received:
**Alvarez et al. 2006: Antithymocyte globulin, rabbit ATG (Thymoglobulin) 2.5 mg/kg IV once per day on days -4 to -2
**HDR-ALLO: ATG (type not specified) 45 mg/kg IV once per day on days -4 to -2
*Cyclosporine starting on day -2 at 1.5 mg/kg IV twice per day
**If no acute GVHD of grade 2 or more, cyclosporine A is tapered down by 10% per week starting on day +90 with planned discontinuation by day +150 (Alvarez et al. 2006) or +180 (HDR-ALLO).
*Methotrexate (MTX) 10 mg/m2 IV once per day on days +1, +3, +6, +11
One course
===Regimen variant #4, 150/40, with alemtuzumab===
Study 	Dates of enrollment 	Evidence
Peggs et al. 2005	1997-10-3 to 2003-08-21	Non-randomized
====Chemotherapy====
*Fludarabine (Fludara) 30 mg/m2 IV once per day on days -7 to -3
*Melphalan (Alkeran) 140 mg/m2 IV once on day -2
====Immunotherapy====
*Allogeneic stem cells transfused on day 0
====GVHD prophylaxis====
*Alemtuzumab (Campath) at varying doses IV (see paper for details)
One course
===References===
#Peggs KS, Hunter A, Chopra R, Parker A, Mahendra P, Milligan D, Craddock C, Pettengell R, Dogan A, Thomson KJ, Morris EC, Hale G, Waldmann H, Goldstone AH, Linch DC, Mackinnon S. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet. 2005 Jun 4-10;365(9475):1934-41. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
#Alvarez I, Sureda A, Caballero MD, Urbano-Ispizua A, Ribera JM, Canales M, García-Conde J, Sanz G, Arranz R, Bernal MT, de la Serna J, Díez JL, Moraleda JM, Rubió-Félix D, Xicoy B, Martínez C, Mateos MV, Sierra J. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: results of a Spanish prospective cooperative protocol. Biol Blood Marrow Transplant. 2006 Feb;12(2):172-83. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
#Anderlini P, Saliba R, Acholonu S, Giralt SA, Andersson B, Ueno NT, Hosing C, Khouri IF, Couriel D, de Lima M, Qazilbash MH, Pro B, Romaguera J, Fayad L, Hagemeister F, Younes A, Munsell MF, Champlin RE. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated MD Anderson Cancer Center experience. Haematologica. 2008 Feb;93(2):257-64. Epub 2008 Jan 26. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article EuroPMC
#HDR-ALLO: Sureda A, Canals C, Arranz R, Caballero D, Ribera JM, Brune M, Passweg J, Martino R, Valcárcel D, Besalduch J, Duarte R, León A, Pascual MJ, García-Noblejas A, López Corral L, Xicoy B, Sierra J, Schmitz N; GEL/TAMO. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma: results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2012 Feb;97(2):310-7. Epub 2011 Oct 11. link to original article dosing details in abstract have been reviewed by our editors link to PMC article EuroPMC
#CUTALLO: de Masson A, Beylot-Barry M, Ram-Wolff C, Mear JB, Dalle S, d'Incan M, Ingen-Housz-Oro S, Orvain C, Abraham J, Dereure O, Charbonnier A, Cornillon J, Longvert C, Barete S, Boulinguez S, Wierzbicka-Hainaut E, Aubin F, Rubio MT, Bernard M, Schmidt-Tanguy A, Houot R, Pham-Ledard A, Michonneau D, Brice P, Labussière-Wallet H, Bouaziz JD, Grange F, Moins-Teisserenc H, Jondeau K, Michel L, Mourah S, Battistella M, Daguindau E, Loschi M, Picard A, Franck N, Maillard N, Huynh A, Nguyen S, Marçais A, Chaby G, Ceballos P, Le Corre Y, Maury S, Bay JO, Adamski H, Bachy E, Forcade E, Socié G, Bagot M, Chevret S, Peffault de Latour R; CUTALLO Investigators; Groupe Français d'Etude des Lymphomes Cutanés; Société Française de Greffe de Moëlle et Thérapie Cellulaire. Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study. Lancet. 2023 Jun 10;401(10392):1941-1950. Epub 2023 Apr 24. link to original article dosing details in supplement have been reviewed by our editors EuroPMC NCT02520908
==Fludarabine & Treosulfan==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator	Comparative Efficacy
Beelen et al. 2019 (MC-FludT.14/L)	2013-2016 	Phase 3 (E-RT-switch-ic)	BuFlu 	Non-inferior EFS24 (primary endpoint)EFS24: 64% vs 50.4%(HR 0.65, 95% CI 0.47-0.90)
Note: This dose of treosulfan was based on a mid-protocol amendment.
====Chemotherapy====
*Fludarabine (Fludara) 30 mg/m2 IV once per day on days -6 to -2
*Treosulfan (Ovastat) 10 g/m2 IV over 2 hours once per day on days -4 to -2
====Immunotherapy====
*Allogeneic stem cells transfused on day 0
One course
===References===
#MC-FludT.14/L: Beelen DW, Trenschel R, Stelljes M, Groth C, Masszi T, Reményi P, Wagner-Drouet EM, Hauptrock B, Dreger P, Luft T, Bethge W, Vogel W, Ciceri F, Peccatori J, Stölzel F, Schetelig J, Junghanß C, Grosse-Thie C, Michallet M, Labussiere-Wallet H, Schaefer-Eckart K, Dressler S, Grigoleit GU, Mielke S, Scheid C, Holtick U, Patriarca F, Medeot M, Rambaldi A, Micò MC, Niederwieser D, Franke GN, Hilgendorf I, Winkelmann NR, Russo D, Socié G, Peffault de Latour R, Holler E, Wolff D, Glass B, Casper J, Wulf G, Menzel H, Basara N, Bieniaszewska M, Stuhler G, Verbeek M, Grass S, Iori AP, Finke J, Benedetti F, Pichlmeier U, Hemmelmann C, Tribanek M, Klein A, Mylius HA, Baumgart J, Dzierzak-Mietla M, Markiewicz M. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial. Lancet Haematol. 2020 Jan;7(1):e28-e39. Epub 2019 Oct 9. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00822393
==Low-dose TBI==
TBI: Total Body Irradiation
===Regimen===
Study 	Evidence
Gyukocza et al. 2010	Non-randomized
====Radiotherapy====
*Total body irradiation (TBI) 200 cGy at a rate of 0.07 to 0.2000 cGy/min on day 0
====Immunotherapy====
*Allogeneic stem cells transfused on day 0
====GVHD prophylaxis====
*One of the following:
**Cyclosporine (dose not specified) PO twice per day, starting on day -3
**Tacrolimus (Prograf) (dose not specified) PO twice per day, starting on day -3
*Mycophenolate mofetil (CellCept) (dose/route not specified), starting on day 0
One course
===References===
#Gyurkocza B, Storb R, Storer BE, Chauncey TR, Lange T, Shizuru JA, Langston AA, Pulsipher MA, Bredeson CN, Maziarz RT, Bruno B, Petersen FB, Maris MB, Agura E, Yeager A, Bethge W, Sahebi F, Appelbaum FR, Maloney DG, Sandmaier BM. Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. J Clin Oncol. 2010 Jun 10;28(17):2859-67. Epub 2010 May 3. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article EuroPMC
==TFC==
TFC: Thiotepa, Fludarabine, Cyclophosphamide
===Regimen===
Study 	Dates of enrollment	Evidence
Corradini et al. 2002 	1998-09 to 2001-01 	Non-randomized
Corradini et al. 2014 (PTCL-06)	2006-11 to 2010-11 	Phase 2
====Chemotherapy====
*Thiotepa (Thioplex) by the following age-based criteria:
**Younger than 45 years old: 5 mg/kg IV every 8 hours on day -6 (3 doses total)
**45 to 60 years old: 5 mg/kg IV every 12 hours on day -6 (2 doses total)
**Older than 60 years old: 5 mg/kg IV once on day -6
*Fludarabine (Fludara) 30 mg/m2 IV once per day on days -4 & -3, given 4 hours after cyclophosphamide
*Cyclophosphamide (Cytoxan) 30 mg/kg IV once per day on days -4 & -3
====Immunotherapy====
*Allogeneic stem cells transfused on day 0
One course
===References===
#Corradini P, Tarella C, Olivieri A, Gianni AM, Voena C, Zallio F, Ladetto M, Falda M, Lucesole M, Dodero A, Ciceri F, Benedetti F, Rambaldi A, Sajeva MR, Tresoldi M, Pileri A, Bordignon C, Bregni M. Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. Blood. 2002 Jan 1;99(1):75-82. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
#PTCL-06: Corradini P, Vitolo U, Rambaldi A, Miceli R, Patriarca F, Gallamini A, Olivieri A, Benedetti F, Todeschini G, Rossi G, Salvi F, Bruno B, Baldini L, Ferreri A, Patti C, Tarella C, Pileri S, Dodero A. Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma. Leukemia. 2014 Sep;28(9):1885-91. Epub 2014 Feb 20. link to original article refers to dosing details in Corradini et al. 2002 EuroPMC EudraCT 2006-004234-33
==TLI==
TLI: Total Lymphocyte Irradiation
===Regimen===
Study 	Dates of enrollment 	Evidence
Lowsky et al. 2005 	2001-12-28 to 2004-12-01	Non-randomized
Kohrt et al. 2009 (BMT153)	2001-12-28 to 2007-09-06	Non-randomized
Note: the schedule for TLI in BMT153 was slightly different, although the manuscript stated that the protocol from Lowsky et al. 2005 was followed. See paper for details.
====Radiotherapy====
*TLI 80 cGy once per day on days -11 to -1 (10 fractions; total dose 800 cGy)
====GVHD prophylaxis====
*Antithymocyte globulin, rabbit ATG (Thymoglobulin) 1.5 mg/kg IV once per day on days -11 to -7
====Immunotherapy====
*Allogeneic stem cells transfused on day 0
One course
===References===
#Lowsky R, Takahashi T, Liu YP, Dejbakhsh-Jones S, Grumet FC, Shizuru JA, Laport GG, Stockerl-Goldstein KE, Johnston LJ, Hoppe RT, Bloch DA, Blume KG, Negrin RS, Strober S. Protective conditioning for acute graft-versus-host disease. N Engl J Med. 2005 Sep 29;353(13):1321-31. Erratum in: N Engl J Med. 2006 Feb 23;354(8):884. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
#BMT153: Kohrt HE, Turnbull BB, Heydari K, Shizuru JA, Laport GG, Miklos DB, Johnston LJ, Arai S, Weng WK, Hoppe RT, Lavori PW, Blume KG, Negrin RS, Strober S, Lowsky R. TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Blood. 2009 Jul 30;114(5):1099-109. Epub 2009 May 7. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00185640
==(90)YFC==
(90)YFC: Ibritumomab tiuxetan, Fludarabine, Cyclophosphamide
===Regimen===
Study 	Dates of enrollment	Evidence
Khouri et al. 2001 (MDACC ID01-233)	1997-2000 	Phase 2
Note: this regimen was specifically addressed in the 2012 update; GVHD prophylaxis details were provided in earlier manuscripts.
====Targeted therapy====
*Rituximab (Rituxan) 250 mg/m2 IV once per day on days -14 & -7
====Radioconjugate therapy====
*Ibritumomab tiuxetan & Indium-111 5 mCi IV once on day -14 for dosimetry
*Ibritumomab tiuxetan & Yttrium-90 (Zevalin) 0.4 mCi/kg (15 MBq/kg) (maximum dose of 32 mCi/1.2 GBq) IV once on day -7
====Chemotherapy====
*Fludarabine (Fludara) 30 mg/m2 IV once per day on days -5 to -3
*Cyclophosphamide (Cytoxan) 750 mg/m2 IV once per day on days -5 to -3
====Immunotherapy====
*Allogeneic stem cells transfused on day 0
====GVHD prophylaxis====
*Antithymocyte globulin, rabbit ATG (Thymoglobulin) by the following donor-based criteria:
**Matched unrelated or mismatched donors: 1 mg/kg IV once per day on days -2 & -1
*Tacrolimus (Prograf) 0.03 mg/kg IV continuous infusion, started on day -2, titrated to whole blood levels of 5 to 15 mg/mL, then PO twice per day upon recovery
*Methotrexate (MTX) 5 mg/m2 (route not specified) once per day on days +1, +3, +6
One course
===References===
#MDACC ID01-233: Khouri IF, Saliba RM, Giralt SA, Lee MS, Okoroji GJ, Hagemeister FB, Korbling M, Younes A, Ippoliti C, Gajewski JL, McLaughlin P, Anderlini P, Donato ML, Cabanillas FF, Champlin RE. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood. 2001 Dec 15;98(13):3595-9. link to original article EuroPMC NCT00048737
##Update: Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS, Medeiros LJ, Fayad L, Samaniego F, Alousi A, Anderlini P, Couriel D, de Lima M, Giralt S, Neelapu SS, Ueno NT, Samuels BI, Hagemeister F, Kwak LW, Champlin RE. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood. 2008 Jun 15;111(12):5530-6. Epub 2008 Apr 14. Erratum in: Blood. 2009 Feb 12;113(7):1613. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article EuroPMC
##Update: Khouri IF, Saliba RM, Erwin WD, Samuels BI, Korbling M, Medeiros LJ, Valverde R, Alousi AM, Anderlini P, Bashir Q, Ciurea S, Gulbis AM, de Lima M, Hosing C, Kebriaei P, Popat UR, Fowler N, Neelapu SS, Samaniego F, Champlin RE, Macapinlac HA. Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood. 2012 Jun 28;119(26):6373-8. Epub 2012 May 14. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article EuroPMC
Category:Allogeneic HSCT regimens
Category:Site-agnostic regimens